Rodman & Renshaw Maintains Omeros(OMER.US) With Buy Rating, Cuts Target Price to $9
Rodman & Renshaw Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $9
Needham Maintains Omeros(OMER.US) With Hold Rating
Omeros Analyst Ratings
Omeros Analyst Ratings
Needham: Reiterates that Omeros (OMER.US) holds the rating.
Omeros Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)
Omeros (OMER) Gets a Hold From Needham
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Omeros Analyst Ratings
Omeros' Clinical Trials Setbacks and Financial Standing Lead to Underperform Rating: An Analysis
UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating
Bank of America Securities Keeps Their Sell Rating on Omeros (OMER)
Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and SAGE Therapeutics (SAGE)
Needham Reaffirms Their Hold Rating on Omeros (OMER)
Omeros Analyst Ratings
UBS Downgrades Omeros to Neutral, Lowers Price Target to $2
Needham Reaffirms Their Hold Rating on Omeros (OMER)
BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target Is $3